science
Definium LSD therapy reduced depression scores in Phase 3 trial
Definium Therapeutics reported that its LSD-based drug DT120 produced larger reductions in depression scores than placebo in a late-stage study. The company said the results move the therapy closer to potential regulatory review.
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Definium Therapeutics said Monday that patients who received a single dose of its LSD therapy DT120 showed a 13.3-point drop on the Montgomery-Åsberg Depression Rating Scale six weeks later, compared with a 5.2-point drop for those on placebo. By 12 weeks the difference narrowed but remained, with treated patients recording an 11-point reduction from baseline versus 3.6 points for the placebo group.
Trial design and next steps The company described the study as its first Phase 3 trial for the drug. It did not release additional details on patient numbers, side effects, or statistical significance. Definium said the data support continued development toward a possible approval application. No regulatory filing timeline was provided.
Transparency
How sources framed this
LeftNeutralRightPromising medical breakthroughRoutine trial update
LeftNeutralRightBreakthroughRoutine
CorroborationModerate · 2 sources
